A detailed history of Meeder Asset Management Inc transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Meeder Asset Management Inc holds 46 shares of BPMC stock, worth $4,351. This represents 0.0% of its overall portfolio holdings.

Number of Shares
46
Previous 30 53.33%
Holding current value
$4,351
Previous $3,000 33.33%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$84.1 - $120.5 $1,345 - $1,928
16 Added 53.33%
46 $4,000
Q2 2024

Aug 08, 2024

SELL
$85.18 - $108.78 $85 - $108
-1 Reduced 3.23%
30 $3,000
Q1 2024

May 07, 2024

BUY
$73.17 - $99.79 $2,268 - $3,093
31 New
31 $2,000
Q4 2021

Feb 11, 2022

SELL
$94.25 - $115.99 $209,894 - $258,309
-2,227 Closed
0 $0
Q2 2021

Aug 09, 2021

SELL
$82.78 - $101.0 $1,572 - $1,919
-19 Reduced 0.85%
2,227 $196,000
Q1 2021

Apr 28, 2021

BUY
$90.71 - $108.28 $203,734 - $243,196
2,246 New
2,246 $218,000
Q4 2020

Feb 09, 2021

SELL
$92.08 - $124.48 $117,678 - $159,085
-1,278 Closed
0 $0
Q3 2020

Nov 02, 2020

BUY
$66.45 - $92.7 $23,922 - $33,372
360 Added 39.22%
1,278 $118,000
Q2 2020

Aug 11, 2020

BUY
$57.09 - $79.27 $42,703 - $59,293
748 Added 440.0%
918 $73,000
Q1 2020

May 15, 2020

BUY
$48.11 - $82.22 $8,082 - $13,812
168 Added 8400.0%
170 $10,000
Q4 2019

Feb 13, 2020

SELL
$66.73 - $82.59 $6,139 - $7,598
-92 Reduced 97.87%
2 $0
Q3 2018

Nov 02, 2018

SELL
$58.91 - $78.32 $12,194 - $16,212
-207 Reduced 68.77%
94 $0
Q2 2018

Jul 24, 2018

BUY
$60.96 - $101.18 $2,560 - $4,249
42 Added 16.22%
301 $0
Q1 2018

May 03, 2018

BUY
$73.28 - $102.95 $2,198 - $3,088
30 Added 13.1%
259 $24,000
Q4 2017

Feb 02, 2018

BUY
$62.91 - $88.32 $11,386 - $15,985
181 Added 377.08%
229 $18,000
Q3 2017

Oct 20, 2017

BUY
$42.37 - $69.67 $2,033 - $3,344
48
48 $3,000

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.65B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Meeder Asset Management Inc Portfolio

Follow Meeder Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Meeder Asset Management Inc with notifications on news.